Is low-dose naltrexone (LDN) safe in pregnancy, and before trying to conceive?
Reviewed 20 sourcesPublished by PepVault
LDN in pregnancy and before IVF: each naltrexone label's own pregnancy and breastfeeding lines, the human studies, the fertility trials and how fast it clears.

- Last reviewed
- Sources
- 20
- Questions
- 6
- Compounds
- 1
The short answer
No study has tested low-dose naltrexone (LDN) in pregnancy. The tablet label finds no adequate studies in pregnant women and says to use it only if the benefit justifies the risk to the fetus. Studies of full-dose naltrexone found no rise in birth defects. No label sets a wait before conceiving; by the labels' half-lives, oral naltrexone is about 97% cleared in three days. Your prescriber and obstetrician decide.
Evidence: No study of LDN in pregnancy: the human data are small cohort studies and case series of full-dose naltrexone in opioid and alcohol use disorder (6 to 121 women on naltrexone each), one unpublished survey, one non-PubMed abstract and animal studies; the fertility studies used full doses (25 to 150 mg where stated).

What do the naltrexone labels say about pregnancy?
LDN (pepvault.app/peptides/low-dose-naltrexone) is naltrexone at a small fraction of the approved 50 mg tablet, prescribed off-label (pepvault.app/glossary/off-label) and usually made by a compounding pharmacy (pepvault.app/glossary/compounded), so no label is written for it. The three kinds of naltrexone label on DailyMed are the nearest thing, and they do not say the same thing. Here is each label's own line, from the versions current on November 20, 2026123:
| Label | Pregnancy | Breastfeeding | Fertility (animal studies) | Half-life |
|---|---|---|---|---|
| Naltrexone tablets, 50 mg (alcohol and opioid dependence) | "No adequate and well-controlled studies in pregnant women"; use "only if the potential benefit justifies the potential risk to the fetus"1 | Unknown whether it enters human milk; "caution should be exercised"1 | At 16 times the recommended dose, more false pregnancies and a lower pregnancy rate in female rats; no effect on male fertility1 | Naltrexone 4 hours; its active breakdown product, 6-beta-naltrexol, 13 hours1 |
| Vivitrol (monthly naltrexone injection) | Case series are "insufficient to identify a drug-associated risk" of birth defects or miscarriage2 | Naltrexone and 6-beta-naltrexol are present in human milk; no data on the infant2 | The same rat findings, at 75 times human exposure2 | 5 to 10 days for both2 |
| Contrave (naltrexone with bupropion, for weight) | "Weight loss offers no benefit to a pregnant patient and may cause fetal harm": stop it when a pregnancy is recognized3 | Both drugs are present in human milk3 | Not studied for the combination; naltrexone alone gave the same rat findings at about 50 times its Contrave dose3 | Naltrexone about 5 hours3 |
Two things in the table matter most. First, the animal warnings are about early fetal loss in rats and rabbits, at 2 to 18 times human exposure depending on the label, and the tablet label found no birth defects in those animals at doses up to 200 mg/kg a day12. Second, none of the three labels sets a time to stop before trying to conceive, and none asks for contraception. That is unlike the semaglutide labels, which say to stop 2 months ahead; the GLP-1 labels are compared in our guide to GLP-1s and pregnancy (pepvault.app/guides/glp-1s-and-pregnancy).
For men, the only data are the rat studies: naltrexone did not change male fertility at the dose that affected females12. No human study of LDN and sperm is on PubMed.

How long does LDN take to leave your body before trying to conceive?
The clock is the half-life (pepvault.app/glossary/half-life), the time it takes for half of the drug in the blood to be cleared. After five half-lives about 3% is left. The label measured naltrexone's levels as proportional to the dose from 50 to 200 mg and gives no half-life for doses below that1, so the table uses the label's figures; a low dose starts with less to clear.
| Form | Half-life on the label | Five half-lives |
|---|---|---|
| Naltrexone tablet | About 4 hours1 | About 20 hours |
| 6-beta-naltrexol (from a tablet) | About 13 hours1 | About 65 hours, under 3 days |
| Contrave's naltrexone | About 5 hours3 | About 25 hours |
| Vivitrol injection | 5 to 10 days2 | 25 to 50 days |
One study measured it directly. In 20 mother-baby pairs from a Tennessee study of naltrexone for opioid use disorder, levels in the mother and in the umbilical cord matched, and none were detected when naltrexone had been stopped more than 60 hours before delivery5. That is close to five half-lives of the 13-hour metabolite.
So oral LDN is gone within days, not weeks. Whether to stop before trying, at a positive test, or not at all is a different question from how fast it clears, and the labels leave it to the prescriber.
PepVault's dose log keeps the date and amount of every LDN dose you log, so the day of your last dose is on record when your prescriber or fertility clinic asks. Log it in PepVault
Does naltrexone help you get pregnant, or help IVF?
The idea is old. The body's own opioids can slow the brain's signal to the ovaries, so by the early 1990s researchers were giving naltrexone to women who were not ovulating. The studies that state a dose used 25 to 150 mg a day, not LDN:
| Study | Who | Dose | Result |
|---|---|---|---|
| Wildt 199311 | 66 women with hypothalamic ovarian failure, where the brain's signal to the ovaries runs low | 25 to 150 mg a day | Cycles normal again in 49; 18 pregnancies in 16 women; no placebo group |
| Manieri 1993, double-blind14 | 22 women with hypothalamic amenorrhea | 50 mg a day or placebo | Periods returned in 2 on naltrexone and 4 on placebo: no benefit |
| Couzinet 199515 | 9 women with hypothalamic amenorrhea | 100 mg a day | No follicle growth on naltrexone alone |
| Roozenburg 199712 | 22 women not ovulating on clomiphene | Naltrexone alone or with an anti-estrogen | 19 ovulated; 12 of the 19 had a pregnancy; no control group |
| Ahmed 200813 | 30 women with PCOS not ovulating on clomiphene | 50 mg a day for 6 months | 3 ovulated on naltrexone alone, none conceived; with clomiphene added, 9 of 27 conceived |
The only placebo-controlled trial in the set found nothing14; the encouraging results come from studies without a comparison group. For LDN itself, ClinicalTrials.gov lists no trial of naltrexone for infertility or IVF as of November 20, 202620. The one published LDN fertility study is from a Baghdad clinic: 350 women with repeated failed embryo transfers, half given 4.5 mg a day before and through the first 12 weeks of pregnancy16. Its abstract reports a thicker womb lining and more pregnancies on LDN, but gives no pregnancy counts, no live births and no word on how women were put into groups, and its lining figures do not add up (26.9 vs 21.1 mm is reported as a 9.8 mm gain)16. The journal is not indexed in PubMed, so treat it as a weak lead, not evidence.
Commonly reported: some fertility doctors prescribe LDN for repeated failed transfers or recurrent miscarriage and keep it going into the first trimester; the published support is the Baghdad abstract and conference talks1617.
What happened in pregnancies exposed to naltrexone?
Nearly all the human data come from women treated with full-dose naltrexone for opioid or alcohol use disorder, compared with women on methadone or buprenorphine. They are observational studies (pepvault.app/glossary/observational-study), and the women in them carry risks of their own, so a difference can come from the illness rather than the drug:
| Study | Who | What it found |
|---|---|---|
| Towers 2020, US, prospective5 | 121 on naltrexone vs 109 on methadone or buprenorphine | Birth defects no different; no miscarriages or stillbirths in either group; newborn withdrawal 8.4% vs 75.2% |
| Kelty 2017, Western Australia, births6 | 68 babies exposed to a naltrexone implant vs 569 unexposed | Birth defects, stillbirths and newborn deaths not different; babies smaller, 3,137 g vs 3,378 g |
| Kelty 2017, Western Australia, mothers7 | Women on a naltrexone implant vs buprenorphine, methadone and controls | Pregnancy loss needing hospital care higher than on buprenorphine and in controls; not different from methadone |
| Wachman 2019, Boston8 | 6 on naltrexone vs 13 matched on buprenorphine | No newborn withdrawal diagnosis on naltrexone vs 92% on buprenorphine; hospital stay 3.2 vs 10.9 days |
| Atluru 2024, systematic review4 | 5 cohort studies comparing naltrexone with methadone or buprenorphine | Gestational age at delivery no different; newborn withdrawal lower on naltrexone in all 3 studies that measured it |
| Contrave clinical trials3 | 21 of 3,024 women became pregnant on Contrave | 11 healthy term births, 4 miscarriages, 3 elective terminations, 3 unknown |
| LDN survey, Boyle 201917 | 237 successful pregnancies only, about half on LDN (anonymous survey by a clinic that prescribes LDN, given as a conference talk, not peer-reviewed) | Preterm birth 6% vs 7%; birth defects in 3 babies vs 2 |
For opioid use disorder, the review's authors call naltrexone "a reasonable" option in pregnancy with "reassuring perinatal outcomes", and say the evidence base is limited4. The one higher number is pregnancy loss in the Australian implant study, which was not different from the methadone group's7. Naltrexone crosses the placenta: cord blood carried 0.74 times the mother's level on tablets and 1.11 times on the injection in a 2026 study of 7 women10.
What if you find out you're pregnant while taking LDN?
There is no LDN-specific answer, because LDN trials shut pregnancy out. The LDN endometriosis trial at Hershey Medical Center excluded women "pregnant, breastfeeding or trying to conceive" and asked the rest to use contraception18; the long COVID trial in British Columbia did the same19. What exists is the tablet label's benefit-against-risk line1, Contrave's stop-at-a-positive-test line for weight3, and the full-dose studies above.
One point is practical for the birth itself: naltrexone blocks opioid pain relief1. In a Boston series of 7 women treated with naltrexone in pregnancy, all delivered vaginally "without any peripartum pain difficulties"9, and in the Tennessee study none was detected when naltrexone had been stopped more than 60 hours before delivery5. Your obstetric team needs to know you take it, so they can plan pain relief, and the decision to stop or continue is theirs and your prescriber's.
When to get help If a pregnancy test turns positive while you take LDN, tell your prescriber and your obstetrician or midwife soon, with the dose and the date you started, and decide with them whether to stop or continue.
Can you take LDN while breastfeeding?
Naltrexone does reach breast milk. The Vivitrol and Contrave labels say naltrexone and 6-beta-naltrexol are present in human milk; Vivitrol's adds that there are no data on the breastfed infant23; the older tablet label says only that it is unknown and to use caution1. The one measurement: one breastfed baby whose mother took full-dose naltrexone received 0.83% of the mother's dose, adjusted for weight, at one month10.
No one has measured LDN in milk. The labels ask the prescriber to weigh the benefits of breastfeeding against the mother's need for the drug23.
When you stop LDN in PepVault, the finished protocol stays under Past protocols with its dates, and a restart after pregnancy or breastfeeding starts a new one beside it, so your prescriber can see both. Log it in PepVault
Sources
- Naltrexone hydrochloride tablets USP 50 mg, prescribing information (RemedyRepack). DailyMed, SPL version 10, published November 16, 2026: Carcinogenesis, mutagenesis, impairment of fertility; Pregnancy; Nursing mothers; Clinical pharmacology. dailymed.nlm.nih.gov
- Vivitrol (naltrexone for extended-release injectable suspension), prescribing information (Alkermes). DailyMed, SPL version 39, published July 24, 2026: 8.1 Pregnancy; 8.2 Lactation; 12.3 Pharmacokinetics; 13.1 Impairment of fertility. dailymed.nlm.nih.gov
- Contrave (naltrexone and bupropion extended-release tablets), prescribing information (Nalpropion). DailyMed, SPL version 27, published November 17, 2025: 8.1 Pregnancy; 8.2 Lactation; 12.3 Pharmacokinetics; 13.1. dailymed.nlm.nih.gov
- Atluru S et al. Naltrexone compared with buprenorphine or methadone in pregnancy: a systematic review. Obstet Gynecol. 2024. PubMed 38227945
- Towers CV et al. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020. PubMed 31376396
- Kelty E, Hulse G. A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates. Drugs. 2017. PubMed 28536981
- Kelty E, Hulse G. A retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls. Drugs. 2017. PubMed 28536980
- Wachman EM et al. Naltrexone treatment for pregnant women with opioid use disorder compared with matched buprenorphine control subjects. Clin Ther. 2019. PubMed 31358302
- Wachman EM et al. Case series of individuals treated with naltrexone during pregnancy for opioid and/or alcohol use disorder. J Addict Med. 2024. PubMed 38354121
- Iannella N et al. Pharmacokinetics of oral and extended-release naltrexone in pregnant and lactating individuals and their infants. J Addict Med. 2026. PubMed 40388713
- Wildt L et al. Treatment with naltrexone in hypothalamic ovarian failure: induction of ovulation and pregnancy. Hum Reprod. 1993. PubMed 8473447
- Roozenburg BJ et al. Successful induction of ovulation in normogonadotrophic clomiphene resistant anovulatory women by combined naltrexone and clomiphene citrate treatment. Hum Reprod. 1997. PubMed 9308800
- Ahmed MI et al. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod. 2008. PubMed 18641399
- Manieri C et al. Naltrexone must not be considered a real therapy in functional hypothalamic amenorrhea: the results of a double blind controlled study. Panminerva Med. 1993. PubMed 8202334
- Couzinet B et al. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab. 1995. PubMed 7608262
- Raffeq ZN, Hamdy AN, Hammo ZSY. The effect of low-dose naltrexone on immunological infertility in women with recurrent implantation failure. Reproductive Health of Woman. 2025;(6):152-159 (abstract record, Zenodo; not indexed in PubMed). zenodo.org
- Boyle PC. Low dose naltrexone in pregnancy. Conference presentation, 2019: anonymous patient survey, not peer-reviewed (RRM Academy library). rrmacademy.org
- ClinicalTrials.gov NCT03970330. Low-dose naltrexone in combination with standard treatment in women with endometriosis (Milton S. Hershey Medical Center): eligibility criteria, accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT05430152. A double-blind randomized trial of low-dose naltrexone for post-COVID fatigue syndrome: eligibility criteria, accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov search: condition infertility, intervention naltrexone (no studies found; also none for female infertility, recurrent pregnancy loss, PCOS or embryo implantation), searched November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.